Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its ...

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings even as sales of its ...

About a dozen lawsuits, citing 2024 studies, allege Ozempic causes a rare eye disorder that leads to irreversible blindness. ...

Novo Nordisk (NVO) won a key case Thursday to stop ... compounded semaglutide — the active ingredient in diabetes drug Ozempic and weight-loss drug Wegovy — next month. That was the deadline ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

And while it's only a matter of time until Ozempic ... Clinical Development, Medical & Regulatory Affairs at the company. "Novo Nordisk's strong legacy in obesity care and decades of scientific ...

In his suit, Todd Engel, of Howard County, accused Novo Nordisk Inc. and 10 other ... The suit cites various research into Ozempic and its side effects, including a study conducted by Harvard ...

She was not involved with the clinical trial. The trial ... that GLP-1s — the class of drugs that includes Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...